MINIREVIEWS

3227 Non-invasive physical therapy as salvage measure for ischemic skin flap: A literature review
Zheng YH, Yin LQ, Xu HK, Gong X

3238 Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
Guo J, Gao XS

ORIGINAL ARTICLE

Retrospective Cohort Study

3252 Burden of atrial fibrillation in patients with rheumatic diseases

Retrospective Study

3265 Observation of the effect of one-to-one education on high-risk cases of diabetic foot
Fu XJ, Hu SD, Peng YF, Zhou LY, Shu T, Song DD

3273 Pediatric Wilson disease presenting as acute liver failure: Prognostic indices

Observational Study

3287 Positive psychological intervention for anxiety, depression and coping in subjects addicted to online games
Gao XJ, Sun JJ, Xiang M

SYSTEMATIC REVIEWS

3294 Cluster headache due to structural lesions: A systematic review of published cases
Long RJ, Zhu YS, Wang AP

META-ANALYSIS

3308 Comparison of smear cytology with liquid-based cytology in pancreatic lesions: A systematic review and meta-analysis
Zhang XH, Ma SY, Liu N, Wei ZC, Gao X, Hao YJ, Liu YX, Cai YQ, Wang JH

CASE REPORT

3320 Bronchial glomus tumor with calcification: A case report
Zhang Y, Zhang QP, Ji YQ, Xu J
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3327</td>
<td>Acute flaccid paralysis and neurogenic respiratory failure associated with enterovirus D68 infection in children: Report of two cases</td>
<td>Zhang Y, Wang SY, Guo DZ, Pan SY, Lv Y</td>
</tr>
<tr>
<td>3334</td>
<td>Skeletal muscle metastases of hepatocellular carcinoma: A case report and literature review</td>
<td>Song Q, Sun XF, Wu XL, Dong Y, Wang L</td>
</tr>
<tr>
<td>3350</td>
<td>Novel intergenic KIF5B-MET fusion variant in a patient with gastric cancer: A case report</td>
<td>Wu ZW, Sha Y, Chen Q, Hou J, Sun Y, Lu WK, Chen J, Yu LJ</td>
</tr>
<tr>
<td>3356</td>
<td>Recurrent perimesencephalic nonaneurysmal subarachnoid hemorrhage within a short period of time: A case report</td>
<td>Li J, Fang X, Yu FC, Du B</td>
</tr>
<tr>
<td>3365</td>
<td>Incremental value of three-dimensional and contrast echocardiography in the evaluation of endocardial fibroelastosis and multiple cardiovascular thrombi: A case report</td>
<td>Sun LJ, Li Y, Qiao W, Yu JH, Ren WD</td>
</tr>
<tr>
<td>3372</td>
<td>Floating elbow combining ipsilateral distal multiple segmental forearm fractures: A case report</td>
<td>Huang GH, Tang JA, Yang TY, Liu Y</td>
</tr>
<tr>
<td>3379</td>
<td>Acute cholangitis detected ectopic ampulla of Vater in the antrum incidentally: A case report</td>
<td>Lee HL, Fu CK</td>
</tr>
<tr>
<td>3394</td>
<td>Tenosynovial giant cell tumor involving the cervical spine: A case report</td>
<td>Zhu JH, Li M, Liang Y, Wu JH</td>
</tr>
<tr>
<td>3418</td>
<td>Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report</td>
<td>Meyer A, Carvalho BJ, Medeiros KA, Pipek LZ, Nascimento FS, Suzuki MO, Munhoz JV, Isuamoto LR, Carneiro-D’Alburquerque LA, Andraus W</td>
</tr>
<tr>
<td>3424</td>
<td>Laparoscopic cholecystectomy for gangrenous cholecystitis in around nineties: Two case reports</td>
<td>Inoue H, Ochiai T, Kabo H, Yamamoto Y, Morimura R, Ikoma H, Otsuji E</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>3432</td>
<td>Radiological insights of ectopic thyroid in the porta hepatis: A case report and review of the literature</td>
<td>Chooah O, Ding J, Fei JL, Xu FY, Yue T, Pu CL, Hu HJ</td>
</tr>
<tr>
<td>3458</td>
<td>Diabetic mastopathy in an elderly woman misdiagnosed as breast cancer: A case report and review of the literature</td>
<td>Chen XX, Shao SJ, Wan H</td>
</tr>
<tr>
<td>3466</td>
<td>Cronkhite-Canada syndrome with steroid dependency: A case report</td>
<td>Jiang D, Tang GD, Lai MY, Huang ZN, Liang ZH</td>
</tr>
<tr>
<td>3472</td>
<td>Extremely rare case of necrotizing gastritis in a patient with autoimmune hepatitis: A case report</td>
<td>Moon SK, Yoo JJ, Kim SG, Kim YS</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of World Journal of Clinical Cases, Nicola Montemurro, MD, PhD, Assistant Professor, Consultant Physician-Scientist, Neurosurgeon, Surgeon, Surgical Oncologist, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa 56126, Italy. nicola.montemurro@unipi.it

AIMS AND SCOPE
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJCC as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3. The WJCC’s CiteScore for 2019 is 0.3 and Scopus CiteScore rank 2019: General Medicine is 394/529.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Yu-Jie Ma; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Dennis A Bloomfield, Sandro Vento, Bao-Gan Peng

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
May 16, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Pure large cell neuroendocrine carcinoma originating from the endometrium: A case report

Ran Du, Feng Jiang, Zheng-Yan Wang, Yan-Qing Kang, Xiu-Yu Wang, Ying Du

ORCID number: Ran Du 0000-0003-3387-7514; Feng Jiang 0000-0001-6164-4491; Zheng-Yan Wang 0000-0003-1134-2973; Yan-Qing Kang 0000-0001-9383-7237; Xiu-Yu Wang 0000-0002-5587-0981; Ying Du 0000-0002-3561-6726.

Author contributions: Du R and Jiang J contributed to the work equally; Du R was a major contributor in reviewing literature and writing the manuscript; Jiang F analyzed and interpreted the patient data; Wang ZY, Wang XY, and Du Y performed the histological examination of the tumor and performed histological diagnosis; Kang YQ analyzed the patient’s magnetic resonance imaging data; All authors read and approved the final manuscript.

Informed consent statement: The present study was approved by the Ethics Committee of Liaocheng People’s Hospital, and written informed consent was obtained from the patient. Written informed consent was obtained from the patient for publication of this case report.

Conflict-of-interest statement: The authors report no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the

Abstract

BACKGROUND
Large cell neuroendocrine carcinoma (LCNEC) of the endometrium is an uncommon and highly aggressive tumor that has not been comprehensively characterized. We report a case of pure endometrial LCNEC and review the current literature of similar cases to raise awareness of the histological features, treatment, and prognosis of this tumor.

CASE SUMMARY
We report the case of a 73-year-old woman who presented with irregular postmenopausal vaginal bleeding. Ultrasonography showed an enlarged uterus and a 5.1 cm × 3.3 cm area of medium and low echogenicity in the uterine cavity. Biopsy by dilatation and curettage suggested poorly differentiated carcinoma. Magnetic resonance imaging revealed a heterogeneously enhanced uterine tumor with diffuse infiltration of the posterior wall of the uterine myometrium and enlarged pelvic lymph nodes. The patient underwent a hysterectomy and bilateral adnexal resection. Gross observation revealed an ill-defined white solid mass of the posterior wall of the uterus infiltrating into the serosa with multiple solid nodules on the serous surface. Microscopically, the tumor cells showed neuroendocrine morphology (organoid nesting). Immunohistochemistry revealed the tumor cells were diffusely positive for the neuroendocrine markers CD56, chromogranin A, and synaptophysin. Thus, the tumor was diagnosed as stage IIIC endometrial LCNEC.

CONCLUSION
Pathologic findings and immunohistochemistry are essential in making a
The manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access**: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source**: Unsolicited manuscript

**Specialty type**: Medicine, research and experimental

**Country/Territory of origin**: China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

**Received**: December 8, 2020
**Peer-review started**: December 8, 2020
**First decision**: January 24, 2021
**Revised**: February 10, 2021
**Accepted**: March 4, 2021
**Article in press**: March 4, 2021
**Published online**: May 16, 2021

**P-Reviewer**: Tajiri K
**S-Editor**: Fan JR
**L-Editor**: Filipodia
**P-Editor**: Xing YX

**Key Words**: Neuroendocrine carcinoma; Large cell; Large cell neuroendocrine carcinoma; Endometrial; Therapy; Prognosis; Case report

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip**: We report the diagnostic and therapeutic experience of a 73-year-old patient with pure endometrial large cell neuroendocrine carcinoma. This article explores the histological features, differential diagnosis, treatment, and prognosis of this tumor and reviews the current literature of similar cases to provide a reference for the diagnosis and treatment of endometrial large cell neuroendocrine carcinoma.

**INTRODUCTION**

Neuroendocrine carcinoma arising from the endometrium is an uncommon entity, accounting for less than 1% of endometrial carcinoma, and large cell neuroendocrine carcinoma (LCNEC) is very rare[1]. LCNEC has an aggressive natural history, a high propensity to metastasize, and poor survival outcomes[1]. To the authors’ knowledge, only 21 cases of LCNEC in the uterine corpus have been published[2-12], and only 12 of these were pure LCNEC (Table 1). Due to the small number of reported cases, knowledge of LCNEC is limited, and the tumor may be difficult to diagnose. Here, we present a case of LCNEC arising in the endometrium. Our findings should raise awareness of the histological features, treatment, and prognosis of this tumor.

**CASE PRESENTATION**

**Chief complaints**

A 73-year-old woman was admitted to Liaocheng People’s Hospital in October 2019 due to irregular postmenopausal vaginal bleeding.

**History of present illness**

The patient had undergone natural menopause 32 yrs ago and had a history of irregular vaginal bleeding in the 3 mo prior to admission. Initially, bleeding was intermittent, lasting for intervals of 2 d. Blood loss was minimal, there was no abdominal pain, and the patient did not seek medical treatment. Twenty days before admission, the patient experienced continuous vaginal bleeding. Blood loss was similar to menstruation, and there was occasional abdominal pain. Two weeks later, the patient experienced massive bleeding and was treated in the gynecology clinic of Liaocheng People’s Hospital.

**History of past illness**

The patient’s medical history was unremarkable.

**Physical examination**

After admission to the hospital, the patient’s temperature was 36.6 °C, heart rate was 76 bpm, respiratory rate was 18 breaths per minute, and blood pressure was 142/73 mmHg. On gynecological examination, when the patient held her breath, the posterior wall of the vagina compressed and partially protruded outside the vagina. The cervix was atrophied, and the uterus was enlarged.
<table>
<thead>
<tr>
<th>Case</th>
<th>Ref.</th>
<th>Age in yr</th>
<th>Presenting symptom</th>
<th>Histology</th>
<th>Immunoprofile positivity</th>
<th>FIGO stage</th>
<th>Surgery</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Nguyen et al[9]</td>
<td>70</td>
<td>PMB</td>
<td>Pure LCNEC</td>
<td>Synaptophysin, chromogranin A, CD56, EMA</td>
<td>IVB</td>
<td>TAH, BSO, OMT</td>
<td>Etoposide, cisplatin</td>
<td>NED 6 mo</td>
</tr>
<tr>
<td>3</td>
<td>Nguyen et al[9]</td>
<td>52</td>
<td>PMB</td>
<td>Pure LCNEC</td>
<td>NSE, synaptophysin</td>
<td>IC</td>
<td>TAH, BSO</td>
<td>Etoposide, cisplatin</td>
<td>DOD 7 mo</td>
</tr>
<tr>
<td>5</td>
<td>Makihara et al[28]</td>
<td>73</td>
<td>Abdominal distension</td>
<td>Pure LCNEC</td>
<td>Synaptophysin, chromogranin A, NSE, P53</td>
<td>IVB</td>
<td>Refused surgery</td>
<td>Refused chemotherapy</td>
<td>DOD 5 wk</td>
</tr>
<tr>
<td>6</td>
<td>Makihara et al[28]</td>
<td>73</td>
<td>PMB</td>
<td>Pure LCNEC</td>
<td>Synaptophysin, chromogranin A, CD56, P53</td>
<td>IIIIC</td>
<td>TAH, BSO, LND, OMT</td>
<td>Cisplatin, irinotecan</td>
<td>Recurrence at 6 mo</td>
</tr>
<tr>
<td>7</td>
<td>Ogura et al[29]</td>
<td>52</td>
<td>Menorrhagia</td>
<td>Pure LCNEC</td>
<td>Synaptophysin, CD56, Ki67</td>
<td>IIIIC</td>
<td>None</td>
<td>None</td>
<td>DOD 1 mo</td>
</tr>
<tr>
<td>8</td>
<td>Mulvany et al[27]</td>
<td>50</td>
<td>PMB</td>
<td>Pure LCNEC</td>
<td>NSE, synaptophysin</td>
<td>IIIIC</td>
<td>TAH, BSO, LND, OMT</td>
<td>Carboplatin, etoposide, RT</td>
<td>AWD 12 mo</td>
</tr>
<tr>
<td>9</td>
<td>Tu et al[15]</td>
<td>51</td>
<td>PMB</td>
<td>Pure LCNEC</td>
<td>CK, P53, CD56, synaptophysin</td>
<td>IVB</td>
<td>TAH, BSO, OMT, suboptimal debulking</td>
<td>Cisplatin, etoposide</td>
<td>DOD 3 mo</td>
</tr>
<tr>
<td>10</td>
<td>Shahabi et al[3]</td>
<td>59</td>
<td>PMB</td>
<td>Pure LCNEC</td>
<td>NSE, chromogranin A, synaptophysin, CD56</td>
<td>IIIIC</td>
<td>TAH, BSO, LND, OMT, suboptimal debulking</td>
<td>Carboplatin, paclitaxel, doxorubicin, etoposide, cisplatin, octreotide</td>
<td>DOD 12 mo</td>
</tr>
<tr>
<td>11</td>
<td>Suh et al[22]</td>
<td>61</td>
<td>Abdominal pain and rapid uterine enlargement</td>
<td>Pure LCNEC</td>
<td>Synaptophysin, CD56</td>
<td>IIIIB</td>
<td>TAH, BSO, OMT</td>
<td>Etoposide/cisplatin, irinotecan/cisplatin, fluorouracil, leucovorin, irinotecan, RT</td>
<td>DOD 23 mo</td>
</tr>
<tr>
<td>12</td>
<td>Present case</td>
<td>73</td>
<td>PMB</td>
<td>Pure LCNEC</td>
<td>Cytokeratin AE1/AE3, chromogranin A, synaptophysin, CD56, P16</td>
<td>IIIIC</td>
<td>TAH, BSO</td>
<td>Paclitaxel, liposome, carboplatin</td>
<td>NED 15 mo</td>
</tr>
</tbody>
</table>

AWD: Alive with disease; BSO: Bilateral salpingo-oophorectomy; DOD: Died of disease; FIGO: International Federation of Gynecology and Obstetrics; LCNEC: Large cell neuroendocrine carcinoma; LND: Lymph node dissection; NED: No evidence of disease; NSE: Neural-specific enolase; OMT: Omentectomy; PMB: Postmenopausal bleeding; PR: Progesterone receptor; RT: Radiotherapy; TAH: Total abdominal hysterectomy.

**Laboratory examinations**

Blood analysis, biochemistry, and urinalysis were normal. Electrocardiogram, chest X-ray, and arterial blood gas were normal.

**Imaging examinations**

Ultrasonography showed an enlarged uterus and a 5.1 cm × 3.3 cm area of medium and low echogenicity in the uterine cavity. Magnetic resonance imaging demonstrated an enlarged uterus and uterine cavity, and the endometrium was thickened, irregular, and protruded into the uterine cavity. A coronal contrast-enhanced computed tomography scan revealed a heterogeneously enhanced uterine tumor with diffuse infiltration of the posterior wall of the uterine myometrium and local roughness of the serosa. Lymph node metastasis was suspected as the internal and external iliac lymph nodes were enlarged. The largest was approximately 1.4 cm and lay along the right external iliac artery. The right internal iliac lymph nodes were partially necrotic (Figure 1). Diagnostic imaging showed no detectable invasion of the tumor into the bladder or rectum.
**Figure 1** Diagnostic imaging of the tumor. A: Sagittal T2-weighted magnetic resonance imaging; B: T2-enhanced magnetic resonance imaging of the pelvis revealed an irregular thickened endometrium and a heterogeneously enhanced uterine tumor with diffuse infiltration of the posterior wall of the uterine myometrium; C: Coronal fast spin echo with T2WI fat suppression revealed an enlarged uterus and uterine cavity and local roughness of the serosa (star) and enlargement and partial necrosis of the right internal iliac lymph node (arrows).

**Pathological examination**

Biopsy by dilatation and curettage suggested poorly differentiated carcinoma. The patient underwent a hysterectomy and bilateral adnexal resection. Pelvic lymph node dissection was not performed as the patient was obese. Gross observations revealed an ill-defined white solid mass that arose from the endometrium and extended through the full thickness of the posterior wall of the myometrium to the uterine serosa. Multiple solid nodules were scattered on the serosa; the largest was 1 cm × 0.8 cm × 0.5 cm.

Microscopically, the poorly differentiated carcinoma infiltrated the muscular layer of the posterior wall of the uterine body to the serosa and did not invade the inner orifice of the cervix. Histologic characteristics included polygonal cells with abundant cytoplasm and a granular eosinophilic or basophilic appearance, large nuclei, prominent nucleoli, “salt and pepper” chromatin, thick nuclear membranes, and ≥ 10 mitoses/high power field without obvious necrosis. The tumor cells showed neuroendocrine morphology (organoid nesting, trabeculae, palisading, or a rosette-like growth pattern) mixed with a solid diffuse pattern (Figure 2). There was obvious vascular invasion and occasional perineural invasion.

Immunohistochemically, the tumor cells were positive for cytokeratin AE1/AE3, chromogranin A, synaptophysin, CD56 (Figure 2) and P16 and negative for P53, estrogen receptor, progesterone receptor, and CD10. The Ki-67 index was approximately 80%. There was no loss of expression of mismatch repair proteins (MLH1, MSH2, MSH6, and MSH3).

**FINAL DIAGNOSIS**

Based on the histological characteristics and results of the immunohistochemical staining, the tumor was diagnosed as LCNEC. Bilateral ovaries and fallopian tubes
Figure 2 Histology and immunohistochemistry. A: Microscopically, tumors showed an organoid pattern of growth with tumor embolism (hematoxylin and eosin, × 40); B: Trabeculae-like pattern (hematoxylin and eosin, × 200); C: Rosette-like pattern with “salt and pepper” chromatin (hematoxylin and eosin, × 400); D-F: Immunohistochemistry revealed positivity for CD56 (D, membranous), synaptophysin (E, cytoplasmic), and chromogranin A (F, cytoplasmic).

were not involved, but a small number of tumor cells were found in pelvic lavage fluid. The clinical postoperative stage was IIIC (International Federation of Gynecology and Obstetrics).

**TREATMENT**

The patient’s recovery after surgery was uneventful. She received four cycles of adjuvant chemotherapy with paclitaxel liposome (240 mg) and lobaplatin (50 mg) over a 3 wk interval at Liaocheng People’s Hospital.
OUTCOME AND FOLLOW-UP

The response to chemotherapy was mild, and there was no obvious alopecia or gastrointestinal reaction. After the fourth chemotherapy treatment, computed tomography of the chest and abdomen and abdominal ultrasound showed no abnormalities. Six months later, computed tomography of the chest and abdomen, abdominal ultrasound, and gynecological examination showed no recurrence or metastasis. At present, after 15 mo, the patient is alive with no evidence of disease.

DISCUSSION

Most reports on LCNEC describe lung malignancies, even though LCNEC only account for 3% of lung cancers. LCNEC of the female genital tract are usually found in the uterine cervix and ovary and rarely involve the endometrium[13]. Endometrial LCNEC may be formed by LCNEC alone or as composites with varying proportions of other tumors, usually endometrioid carcinoma. Previous studies have described the clinicopathological features of endometrial neuroendocrine carcinoma. Pocrnich et al[14] reported on 25 cases, including large cell type, small cell type, or a mixture of both. Of these, 22 cases had a LCNEC component and 3 cases had a small cell neuroendocrine carcinoma component[14]. Rivera et al[1] reported a case of LCNEC associated with low-grade endometrial stromal sarcoma. In the present case, the tumor was pure LCNEC.

A literature review revealed published studies describing endometrial LCNEC included patients aged 51 to 73 years (median: 60 years; mean: 61 years) (Table 1), suggesting the disease mainly affects older postmenopausal women. The most common clinical manifestation of endometrial LCNEC was abnormal or postmenopausal bleeding. The maximum reported endometrial LCNEC tumor dimensions ranged from 0.8 to 12 cm (median: 6.0 cm). Most publications showed endometrial LCNECs had neuroendocrine morphology with an insular (organoid nesting) and admixed solid (diffuse) growth pattern. Most tumors had high mitotic activity, areas of necrosis, and vascular invasion and expressed at least one neuroendocrine marker (chromogranin, synaptophysin, or CD56)[14,15]. The Ki-67 proliferation index was very high (> 80%)[16,17]. Immunohistochemical staining of four cases of pure LCNEC, three cases of LCNEC associated with endometrioid carcinoma, and one case of small cell neuroendocrine carcinoma associated with endometrioid carcinoma demonstrated abnormalities of mismatch repair protein expression[14]. In the present case, the tumor was diffusely and strongly positive for synaptophysin, chromogranin A, and CD56, and there was no loss of mismatch repair expression.

The genetic profile of endometrial LCNEC is unknown. However, endometrioid carcinoma and endometrioid LCNEC share a gene mutation signature with identical alterations in phosphatase and tensin homolog, PIK3CA, and fibroblast growth factor receptor 3, suggesting a common origin[18].

Routine tissue sampling may misdiagnose or miss endometrial LCNEC. Endometrial biopsy provided only one pathologic diagnosis among 20 cases of endometrial LCNEC, even though endometrial assessment by biopsy or sampling of endometrial cells has a sensitivity of 81% for detecting endometrial carcinoma and atypical hyperplasia in women with abnormal uterine bleeding[19,20]. Consistent with this, consensus suggests that LCNEC of the lung should not be made on cytology or biopsy alone with the final diagnosis based on resected specimens[21].

Due to its rarity, there is no standard therapy for LCNEC[22], and most clinical recommendations are relevant to LCNEC of the lung or cervix, including the use of first-line chemotherapy with irinotecan/cisplatin therapy[22]. For early stage endometrial LCNEC, consensus favors surgery followed by chemotherapy with etoposide and platinum-based agents[20]. Surgical approaches to endometrioid histology include hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection, while omentectomy is performed for nonendometrioid carcinoma[22]. In the studies identified in our literature review, six patients with endometrial LCNEC were treated with standard surgical methods relevant to nonendometrioid carcinoma with various outcomes. Complete surgery provided better outcomes compared to incomplete surgery[23]. At present, there is no established first-line chemotherapy regimen for endometrial LCNEC. Etoposide and cisplatin are generally preferred in LCNEC of the cervix with an 83% recurrence free survival reported at 3 yrs[24]. Paclitaxel and platinum-based chemotherapy has become a first-line chemotherapy
regimen for gynecological malignant tumors such as endometrial cancer and ovarian cancer, especially for patients with aggressive tumors who have a high risk of recurrence. Lobaplatin is more effective for controlling disease progression and associated with less toxicity and better patient quality of life than carboplatin\cite{25,26}. Therefore, this patient was treated with liposomal paclitaxel combined with lobaplatin, which achieved good efficacy with mild side effects.

Differential diagnosis for endometrial LCNEC includes grade 3 endometrioid carcinoma, undifferentiated carcinoma, and primitive neuroectodermal tumor. Grade 3 endometrioid carcinoma express neuroendocrine markers but lack nest-like, trabecular, or ribbon-like polygonal cells. Undifferentiated carcinomas resemble LCNEC but may show diffuse staining for neuroendocrine markers\cite{6}. LCNECs are identified when neuroendocrine markers are expressed in > 10% of tumor cells. Primitive neuroectodermal tumor usually stain positive for synaptophysin but are typically chromogranin negative and show neuroectodermal differentiation (fibrillary background, rosettes, ganglion cells, astrocyte-like cells) and are negative for cytokeratins\cite{8}. Endometrial LCNECs do not show specific characteristics on imaging. Magnetic resonance imaging findings resemble other poorly differentiated carcinomas and uterine sarcoma, showing an ill-defined endometrial-myometrial border and a heterogeneous mass with necrosis and hemorrhage\cite{27}. Preoperative magnetic resonance imaging has clinical utility for assessing the extent of endometrial LCNEC.

Stage is an important predictor of prognosis in patients with cancer\cite{22}. Among the studies identified in our literature review, 11 endometrial LCNECs were stage III-IV (91.7%) and 1 was stage I.C. Among the 12 patients, 8 (66.7%) died within 7.3 mo of diagnosis. However, several studies show International Federation of Gynecology and Obstetrics stage was not a significant predictor of prognosis in patients with endometrial LCNECs on multivariate analysis\cite{22,23}, possibly because neuroendocrine carcinomas are invasive and aggressive, with pure neuroendocrine carcinomas progressing more rapidly and having a worse prognosis than mixed neuroendocrine carcinomas\cite{23}.

**CONCLUSION**

Endometrial LCNEC is extremely uncommon, especially pure LCNEC, which is likely under-reported and misdiagnosed. Correct diagnosis of endometrial LCNEC is important as it is a highly aggressive tumor that is associated with poor survival outcomes, but there is no evidence-based therapeutic regimen. Here, we describe a case of pure endometrial LCNEC and review the current literature of similar cases to raise awareness of the histological features, treatment, and prognosis of this tumor.

**REFERENCES**


Albores-Saavedra J, Martinez-Benitez B, Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol 2008; 27: 333-339 [PMID: 18580310 DOI: 10.1097/PJP.0b013e31815d0e06]


Makihara N, Maeda T, Nishimura M, Deguchi M, Sonoyama A, Nakabayashi K, Kawakami F, Itoh
T, Yamada H. Large cell neuroendocrine carcinoma originating from the uterine endometrium: a report on magnetic resonance features of 2 cases with very rare and aggressive tumor. Rare Tumors 2012; 4: e37 [PMID: 23087793 DOI: 10.4081/rt.2012.e37]
